Endocrine Society announces inaugural Rare Endocrine Disease Fellows Program

The Endocrine Society is pleased to announce its Rare Endocrine Disease (RED) Fellows Program designed to equip early career physicians with the knowledge and practical skills needed to improve outcomes for people living with rare endocrine diseases.

The program was developed in partnership with the National Organization for Rare Disorders (NORD) and addresses critical gaps in awareness, diagnosis and care of rare endocrine diseases.

The program consists of two core components:

• An immersive in-person workshop held April 17-18 at the Endocrine Society Headquarters in downtown Washington, D.C., where fellows can engage directly with leading experts in rare endocrine diseases, participate in interactive, case-based discussions, and gain access to the NORD rare patient panel; and
• Five on-demand, multi-module courses featuring short micro-lessons covering individual rare endocrine diseases.

The program accepts up to 50 domestic fellows, and the deadline for program directors and other faculty to nominate a fellow is March 2, 2026.

For more details on the program, including eligibility, learning objectives and the program agenda, visit endocrine.org/education-and-training/rare-endocrine-disease-fellows-program.

This program is supported by educational grants from Alexion Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., BridgeBio Pharma, Inc., Chiesi USA, Inc., Corcept Therapeutics, Inc., and Crinetics Pharmaceuticals, Inc.